With the advent of highly active antiretroviral therapy (HAART) in 1996, morbidity and mortality rates in patients with human immunodeficiency virus (HIV) infection have declined significantly [1] . The vast majority of patients receiving treatment will maintain an undetectable viral load and will not develop AIDS [2] . Suboptimal medication adherence by patients may lead to selection of mutations conferring resistance against HAART and then to virologic failure, which continues to be a challenge despite simplification of HAART, with fewer adverse effects and pill burden. Whereas the incidence of HIV remains stable, its prevalence has been steadily rising during the last decade [3] owing to the declining mortality rate.
Computational models have shown that it would take about 70 years of complete viral suppression for a patient to achieve virologic cure of HIV [4] . However, a case report from Germany describes a patient cured of HIV infection after undergoing allogeneic hematopoietic stem cell transplantation (HSCT) [5] from a CCR5∆32 homozygous donor for acute myeloid leukemia. This has generated extensive scientific inquiry into the potential role of HSCT in achieving virologic cure of HIV. A recent study of allogeneic HSCT in 2 HIV-infected patients in Boston reported sustained remission of HIV for 12 and 32 weeks after stopping HAART, but this was followed by viral rebound [6] .
Another recent study showed that autologous HSCT for HIVrelated lymphoma is safe and effective in patients with HIV infection [7] . Several clinical trials are ongoing to study outcomes of HSCT in HIV-associated cancers. However, the published data on outcomes of HSCT in HIV-infected patients are limited, especially in allogeneic HSCT [8] . Initial studies have suggested that outcomes in HIV-positive patients who undergo HSCT are similar to those in HIV-negative patients [9, 10] . However, the studies are limited by small sample size or lack of recent data [11] . Therefore, our aim was to analyze the outcomes in HIVpositive patients who have undergone HSCT since 1998 when HAART was available, to better navigate future studies on HIV cure through HSCT. We studied the outcomes of autologous and allogeneic HSCT in HIV-positive patients and compared them with outcomes in HIV-negative patients, using the Nationwide Inpatient Sample (NIS) data set from 1998 to 2012.
METHODS

Data Source
The NIS is an all-payer database of hospitalizations in the United States developed by Healthcare Cost and Utilization Project, which contains data on >8 million discharges every year. The NIS is a 20% stratified sample of all US hospitals and uses National Health Survey strata to weight each participating hospital. Each observation is assigned a discharge weight, which is used to project to a nationally representative population. Each observation represents 1 hospitalization and contains data on primary discharge diagnoses and up to 24 secondary discharge diagnoses. In addition, it contains the information on demographic characteristics of patients, 1 primary procedure and up to 14 secondary procedures performed during the same hospitalization, in-hospital mortality status, characteristics of the hospital, insurance status, total charges for the hospitalization, and length of stay. The International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) codes are used to record discharge diagnoses and procedures. The details of NIS methods have been previously published by Healthcare Cost and Utilization Project [12] .
Study Design and Patients
We queried NIS data from 1998 to 2012 for HSCT using ICD-9-CM procedure code 41.0x. The HIV status of the patient was identified by the presence of ICD-9-CM diagnostic codes 042, 043, 044, V08, and 079.53 in primary or secondary discharge diagnoses for the hospitalization.
Outcomes
The primary outcome was the in-hospital mortality rate. Secondary outcomes included in-hospital complications of HSCT (need for intubation, sepsis, bacteremia, opportunistic infections, development of graft-vs-host disease [GVHD], stomatitis, or need for total parenteral nutrition [TPN] ) and venous thromboembolism.
Variables
Type of HSCT, stem cell source, use of total body radiation, and complications of HSCT described above were defined by using ICD-9-CM codes. Deyo's modification of the Charlson comorbidity index was used to define the severity of comorbid conditions [13] . The total charges for each hospitalization were adjusted for inflation by using Consumer Price Index data from the Bureau of Labor Statistics [14] .
Statistical Analysis
SAS software (version 9.3; SAS Institute) was used for all analysis. Survey procedures were used to adjust for the stratified cluster design of the NIS, using DOMAIN, STRATA, CLUSTER, and WEIGHT statements. To test for differences, we used χ 2 tests for categorical and unpaired t or Mann-Whitney U tests for continuous variables. If the univariate and matched-pairs analyses showed significant difference in outcomes between HIV-positive and HIV-negative patients, we performed multiple logistic regression analysis to determine the impact of HIV status on primary and secondary outcomes, controlling for confounders (age, sex, comorbid conditions, type of HSCT, stem cell source, and total body irradiation). Differences were considered significant at P < .05.
Matched-Pair Analysis
Using an individual matching macro (GMATCH) available on Mayo Clinic's Web site [15] , we matched each Abbreviations: CCI, Charlson comorbidity index; HIV, human immunodeficiency virus; HSCT, hematopoietic stem cell transplantation; SE, standard error of the mean. a P <. 05 at 95% confidence interval. b Deyo's modification of the CCI was used to define the severity of comorbid conditions [13] .
HIV-positive patient with up to 5 HIV-negative patients to generated matched-pair data set. Matching variables included age (±5 years), sex (exact match), Charlson comorbidity index (±2), underlying indication of HSCT (exact match), type of HSCT (exact match), source of stem cells (exact match), total body irradiation (exact match), and calendar year (±2 years). The Cochran Mantel-Hanzel χ 2 test was used to test difference between categorical variables in matched data sets.
RESULTS
From 1998 to 2012, the NIS included 39 517 patients who underwent HSCT (Table 1) . After application of discharge weights, they were representative of 192 562 similar patients in United States. Among these, 108 patients (weighted n = 520) were HIV positive. A higher proportion of HIV-positive patients were male compared with HIV-negative patients (84.2% vs 56.6%, respectively) a higher proportion were African American (16.1% vs 7.1%;), and a higher proportion underwent autologous HSCT (84.5% vs 58.3% (all significant at P <.001). A lower proportion of HIV-positive than HIV-negative patients received total body radiation as a conditioning regimen (7.2% vs 15.3%, respectively; P = .04). The number of HIV-positive patients undergoing HSCT has been constantly increasing, from 81 patients between 1998 and 2002 to 278 between 2008 and 2012 ( Figure 1) . In allogeneic HSCT, HIV-positive patients had significantly higher rates of nontuberculous Mycobacterium (NTM) or cytomegalovirus (CMV) infection in univariate analysis (NTM, 5.4% vs 0.2%, respectively [P < .001]; CMV, 22.2% vs 6.3% [P = .04]). The higher odds of NTM and CMV in HIV-positive patients were consistent in matched-pairs and multivariate analysis (Table 2 and Figures 2A and 3A) . Although invasive fungal infections (IFIs) were more common in HIV-positive patients in univariate (29% vs 12.3%; P = .02) and multivariate (odds ratio [OR], 4.76; P = .004) analyses, there was no difference in the odds of IFI in matched-pairs analysis. Similarly, the incidence of stomatitis was lower in HIV-positive patients in univariate (24.2% vs 46%; P = .01) and multivariate (OR, 0.4; P = .03) analyses, but there was no difference in the odds of stomatitis in matched-pairs analysis (Table 2 and Figures 2A and 3A) . Despite these differences, there was no difference in inpatient mortality rates between HIV-positive and HIV-negative patients (11.5% vs 10.2%; P = .8), nor was there any difference in intubation, sepsis, bacteremia, GVHD, TPN use, or venous thromboembolism. In autologous HSCT, HIV-positive patients had higher rates of herpes simplex virus (HSV) infection (10.7% vs 2.0% in HIVnegative patients; P < .001). However, there was no difference in rates of invasive HSV between the 2 groups. Other outcomes were also similar in the 2 groups (Table 2 and Figures 2B and  3B ). Univariate analysis did not show a significant difference in in-hospital mortality rates (2.2% vs 2.2%, respectively; P > .99), nor any significant difference in intubation, sepsis, bacteremia, stomatitis, TPN, or venous thromboembolism. Comparably, matched-pair analysis also showed no significant difference in mortality rates between HIV-positive and HIV-negative patients ( Figure 2B ), as well as no significant differences in sepsis, bacteremia, NTM, CMV, stomatitis, or TPN ( Figure 2B ). Multivariate analysis echoed these results, showing no significant difference in sepsis, bacteremia, stomatitis, or TPN (Table 3) .
Our study also evaluated multivariate predictors of the in-hospital mortality rate. For both allogeneic and autologous HSCT recipients, HIV status had no impact on in-hospital mortality rate (OR, 1.27 [P = .1] for allogeneic and 0.95 [P = .9] for autologous HSCT). For allogeneic HSCT, significant predictors of higher mortality rates included bacteremia (OR, 3.33, opportunistic infections (2.23), GVHD (1.76), and intubation (44.05) (all P < .001). For autologous HSCT, significant predictors of higher mortality rates were bacteremia (OR, 3.29), opportunistic infection (1.92), and intubation (115.28) (all P < .001).
DISCUSSION
With wide availability of HAART, HIV-positive patients are living longer, which has lead to increase in incidence of HIVassociated cancers [16] . HSCT is being used more frequently to treat these conditions. HIV-infected patients are more immunocompromised than the non-HIV-infected patients at baseline [17] , and HSCT makes them even more immunocompromised, especially allogeneic HSCT. Our study shows that HIV-positive patients are more likely than HIV-uninfected patients to acquire NTM or CMV infection during hospitalization for HSCT. They are not at higher risk of other serious complications of HSCT (sepsis, bacteremia, and GVHD).
In our study, we found that HIV-positive patients had significantly higher risks of NTM and CMV infection in univariate, Figure 2 . Impact of human immunodeficiency virus infection on outcomes of allogeneic (A) and autologous (B) hematopoietic stem cell transplantation by matched-pairs analysis. Abbreviations: CL, confidence limit; CMV, cytomegalovirus; GVHD, graft-vs-host disease; HIV, human immunodeficiency virus; HSCT, hematopoietic stem cell transplantation; HSV, herpes simplex virus; IFI, invasive fungal infection; LCL, lower confidence limit; NTM, nontuberculous Mycobacterium; ODI, other documented infections; OR, odds ratio; TPN, total parenteral nutrition; UCL; upper confidence limit.
matched-pair, and multivariate analyses for allogeneic HSCT. CMV infection may be higher in HIV-positive patients for 2 reasons: higher CMV seroprevalence and more impaired T-cell-mediated immunity from onset. IFIs were more common in HIV-positive patients, and stomatitis less common, in both univariate and multivariate but not in matched-pair analysis; these differences are probably due to heterogeneity of conditioning regimens, given that the differences were not statistically significant in matched-pair analysis.
We also found that in-hospital mortality rates were similar in both groups, as were the rates of GVHD. A study by Gupta et al [11] published in 2009 also showed no difference in GVHD rates between HIV-positive and HIV-negative patients, consistent with our results. That study also showed that survival was in fact prolonged in several patients, concluding that allogeneic HSCT should not be excluded for HIV-positive patients where indicated. A 2011 review article analyzed data from >25 years of allogeneic HSCT in patients with HIV-1 infection [8] ; the authors suggested that survival rates after allogeneic HSCT had improved over the years and that the procedure should thus be considered an option for patients who are HIV positive and have an appropriate underlying indication. Our results support these conclusions and provide more data regarding the safety of allogeneic HSCT in HIV-positive patients.
With regard to autologous HSCT, our study showed that HSV infection was more common in HIV-positive patients; however there was no difference in the rates of invasive HSV infection between the 2 HIV groups. Other outcomes, including sepsis, bacteremia, NTM, CMV, stomatitis, and TPN use, were also similar in the 2 groups. Our study conclusions for autologous HSCT paralleled those found in other studies. In a 2009 study by Díez-Martín et al [10] , overall survival and progression-free survival rates were similar in HIV-positive and HIV-negative groups; the main cause of death was disease relapse and progression.
Our data support those conclusions, in that patients who are HIV positive should not be excluded from undergoing autologous HSCT, and serious inpatient complications of autologous HSCT in HIV-positive patients are similar to those in HIV-negative patients. Nonetheless, proper precautions, such as infection prophylaxis and monitoring of immune recovery, should be taken. A previous study by Simonelli et al [18] showed that infectious complications, specifically CMV infections, were more common in HIV-infected patients during the first 3 months after autologous HSCT. Hence, continued close monitoring is warranted in HIV-infected patients after discharge, even those undergoing autologous HSCT. The major drawback of our study is that the patients who underwent HSCT were not a randomized group of patients. Thus, we cannot exclude the possibility that HIV-positive patients who underwent HSCT differed from those who did not have HIV infection. Furthermore, the NIS database does not contain information on long-term follow-up for patients undergoing HSCT, so mortality rates and complications after hospital discharge could not be assessed. In addition, the NIS database does not contain data on CD4c ell counts or HIV viral load, and, data on specific ART and conditioning regimens and GVHD prophylaxis were also not available. Finally, NIS is an administrative data set, and thus recorded discharge diagnoses and procedures are not always correct. Because the data are completely anonymous, it is not possible to validate them. Owing to these limitations, the findings of our study are primarily hypothesis generating. Because NIS data do not contain information on outpatient treatments or prevalence, it was not possible to assess whether or not the number of HSCTs as a proportion of the total number of HIV-positive persons alive each year changed over time.
In summary, the frequency of HSCT is increasing in HIVpositive patients with underlying indication for HSCT. Rates of serious in-hospital complications of HSCT are similar in HIVpositive and HIV-negative patients for allogeneic and autologous HSCT, which can be safely performed in HIV-positive patients.
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